60 DEGREES PHARMACEUTICALS INC. - COMMON STOCK

0,2230

16-мая-24 15:59:18

15 мин. задержка

Акции

+0,0099

+4,65%

Сегодняшний диапазон

0,2100 - 0,2247

ISIN

N/A

Источник

NASDAQ

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

15 май 2024 13:45:03 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

08 май 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

02 май 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

03 апр 2024 07:58:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

14 мар 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

20 фев 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

08 фев 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

31 янв 2024 11:15:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

30 янв 2024 09:00:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

22 янв 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

16 янв 2024 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

26 дек 2023 07:59:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

15 ноя 2023 07:29:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

19 окт 2023 08:31:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

12 окт 2023 16:16:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

18 сен 2023 16:16:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

06 сен 2023 07:31:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

30 авг 2023 07:32:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

22 авг 2023 07:31:00 Источник Nasdaq GlobeNewswire
60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

15 авг 2023 07:31:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.